Skip to main content
PMC home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2004 Sep;65(5):383–397. doi: 10.1016/j.curtheres.2004.10.004

Comparison of the effects of parecoxib and diclofenac in preemptive analgesia: A prospective, randomized, assessor-blind, single-dose, parallel-group study in patients undergoing elective general surgery

Parina Bajaj 1, Chetna C Ballary 2, Neelesh A Dongre 2, Vidyagauri P Baliga 2, Anish A Desai 2,**
PMCID: PMC3964533  PMID: 24672093

Abstract

Background:

Preoperative administration of analgesics may prevent or reducehyperalgesia, inhibit inflammation, and reduce pain by reducing the synthesis of prostaglandins in response to tissue damage caused by surgery. Nonsteroidal anti-inflammatory drugs (NSAIDs) are a potent, widely used class of analgesic agents; however, they may not be as effective as selective cyclooxygenase (COX)-2 inhibitors.

Objective:

The aim of this study was to compare the efficacy and tolerabilityof the COX-2 inhibitor parecoxib sodium and the NSAID diclofenac sodium as preemptive analgesics in patients undergoing elective general surgery.

Methods:

This was a prospective, randomized, assessor-blind, single-dose,parallel-group, comparative trial. Patients aged 18 to 65 years undergoing elective general surgery were enrolled. A single IM injection of parecoxib 40 mg or diclofenac 75 mg was administered 30 to 45 minutes before the induction of anesthesia. Surgery was performed as per standard protocol. The primary measures of efficacy were pain intensity score (measured on a visual analog scale [VAS]), pain relief score, duration of analgesia, and platelet aggregation response to adenosine diphosphate. Tolerability assessment included monitoring of treatment-emergent adverse events (AEs), physical examination, laboratory analysis, electrocardiography, and chest radiography.

Results:

Eighty patients (56 men, 24 women; mean [SD] age, 45.96 [12.83] years) were enrolled in the study (40 patients per treatment group). All patients completed the trial. No pain was reported by any patient in the parecoxib group up to 12 hours; in the diclofenac group, no pain was reported up to 6 hours. At 12 hours, the mean (SD) VAS score was 2.33 (1.39) (moderate pain) in the diclofenac group and 0 (no pain) in the parecoxib group (P < 0.05). At 12 hours, total pain relief was reported by all 40 patients (100.0%) in the parecoxib group but by none (0.0%) in the diclofenac group, and 2 patients in the diclofenac group (5.0%) reported good pain relief (between-group difference for total + good pain relief, P < 0.05). Mean (SD) duration of analgesia was significantly longer in the parecoxib group than in the diclofenac group (19.48 [5.61] hours vs 8.32 [4.11 ] hours; P < 0.05). Platelet aggregation was significantly inhibited in the diclofenac group (change from baseline, 64.0%) but not in the parecoxib group (change from baseline, 12.0%) (P < 0.05). Both regimens were well tolerated, and no AEs were reported.

Conclusions:

In this study of patients undergoing elective general surgery,patients treated with the COX-2 specific inhibitor parecoxib experienced no pain at 12 hours, and the treatment was well tolerated. The results of this study suggest that good postoperative analgesia and minimal interference with platelet function may make parecoxib an alternative to the nonselective NSAID diclofenac in providing preemptive analgesia in patients undergoing general surgery.

Key words: preemptive analgesia, parecoxib, valdecoxib, diclofenac, general surgery

Full Text

The Full Text of this article is available as a PDF (721.4 KB).

References

  • 1.Desjardins P.J., Shu V.S., Recker D.P. A single-dose preoperative oral dose of valdecoxib, a new cyclooxygenase-2 specific inhibitor, relieves post-oral surgery or bunionectomy pain. Anesthesiology. 2002;97:565–573. doi: 10.1097/00000542-200209000-00008. [DOI] [PubMed] [Google Scholar]
  • 2.Weissmann G. The actions of NSAIDs. Hosp Pract (Off Ed) 1991;26:60–68. doi: 10.1080/21548331.1991.11705279. [DOI] [PubMed] [Google Scholar]; Weissmann G. The actions of NSAIDs. Hosp Pract (Off Ed) 1991;26:71–72. doi: 10.1080/21548331.1991.11705279. [DOI] [PubMed] [Google Scholar]; Weissmann G. The actions of NSAIDs. Hosp Pract (Off Ed) 1991;26:75–76. doi: 10.1080/21548331.1991.11705279. [DOI] [PubMed] [Google Scholar]
  • 3.Noveck R.J., Laurent A., Kuss M. Parecoxib sodium does not impair platelet function in healthy elderly and non-elderly individuals: Two randomised, controlled trials. Clin Drug Invest. 2001;21:465–476. [Google Scholar]
  • 4.Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231:232–235. doi: 10.1038/newbio231232a0. [DOI] [PubMed] [Google Scholar]
  • 5.Davies P., Bailey P.J., Goldenberg M.M., Ford-Hutchinson A.W. The role of arachidonic acid oxygenation products in pain and inflammation. Annu Rev Immunol. 1984;2:335–357. doi: 10.1146/annurev.iy.02.040184.002003. [DOI] [PubMed] [Google Scholar]
  • 6.Garcia Rodriguez L.A., Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343:769–772. doi: 10.1016/s0140-6736(94)91843-0. [DOI] [PubMed] [Google Scholar]
  • 7.Dubois R.N., Abraham S.B., Crofford L. Cyclooxygenase in biology and disease. FASEB J. 1998;12:1063–1073. [PubMed] [Google Scholar]
  • 8.Karim A., Laurent A., Slater M.E. A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjects. J Clin Pharmacol. 2001;41:1111–1119. doi: 10.1177/00912700122012607. [DOI] [PubMed] [Google Scholar]
  • 9.Garcia Rodriguez L.A., Cattaruzzi C., Troncon M.G., Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med. 1998;158:33–39. doi: 10.1001/archinte.158.1.33. [DOI] [PubMed] [Google Scholar]
  • 10.Choo V., Lewis S. Ketorolac doses reduced. Lancet. 1993;342:109. doi: 10.1016/0140-6736(93)91304-5. [DOI] [PubMed] [Google Scholar]
  • 11.Gillis J.C., Brogden R.N. Ketorolac. Reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs. 1997;53:139–188. doi: 10.2165/00003495-199753010-00012. [DOI] [PubMed] [Google Scholar]
  • 12.Parfitt K. Martindale: The Complete Drug Reference. vol 121. January–September 2004. Diclofenac. (Thomson Micromedex® Health Care Series 1974–2004). [CD-ROM] [Google Scholar]
  • 13.Derendorf H., Mullersman G., Barth J. Pharmacokinetics of diclofenac sodium after intramuscular administration in combination with triamcinolone acetate. Eur J Clin Pharmacol. 1986;31:363–365. doi: 10.1007/BF00981139. [DOI] [PubMed] [Google Scholar]
  • 14.Wilson Y.G., Rhodes M., Ahmed R. Intramuscular diclofenac sodium for postoperative analgesia after laparoscopic cholecystectomy: A randomised, controlled trial. Surg Laparosc Endosc. 1994;4:340–344. [PubMed] [Google Scholar]
  • 15.O'Hanlon J.J., Beers H., Huss B.K., Milligan K.R. A comparison of the effect of intramuscular diclofenac, ketorolac or piroxicam on postoperative pain following laparoscopy. Ulster Med J. 1996;65:51–54. [PMC free article] [PubMed] [Google Scholar]
  • 16.Ahrens N., Schewior L., Garbe E. Massive hemolysis after intramuscular diclofenac in a patient who apparently tolerated oral medication. Vox Sang. 2004;86:71–74. doi: 10.1111/j.0042-9007.2004.00389.x. [DOI] [PubMed] [Google Scholar]
  • 17.Verfaillie G., Knape S., Corne L. A case of fatal necrotizing fasciitis after intramuscular administration of diclofenac. Evr J Emerg Med. 2002;9:270–273. doi: 10.1097/00063110-200209000-00013. [DOI] [PubMed] [Google Scholar]
  • 18.Munsterhjelm E., Niemi T.T., Syrjala M.T. Propacetamol augments inhibition of platelet function by diclofenac in volunteers. Br J Anaesth. 2003;91:357–362. doi: 10.1093/bja/aeg195. [DOI] [PubMed] [Google Scholar]
  • 19.Tyutyulkova N., Gorantcheva Y., Lisitchkov T. Effect of diclofenac sodium (feloran) on platelet aggregation. Methods Find Exp Clin Pharmacol. 1984;6:21–25. [PubMed] [Google Scholar]
  • 20.Price A.J., Obeid D. Spontaneous non-gastrointestinal bleeding associated with diclofenac. Lancet. 1989;2:1520. doi: 10.1016/s0140-6736(89)92958-9. Letter. [DOI] [PubMed] [Google Scholar]
  • 21.Robinson P.M., Ahmed I. Diclofenac and post-tonsillectomy haemorrhage. Clin Otolaryngol. 1994;19:344–345. doi: 10.1111/j.1365-2273.1994.tb01243.x. [DOI] [PubMed] [Google Scholar]
  • 22.Physicians' Desk Reference. 52nd ed. Medical Economics Co; Montvale, NJ: 1998. pp. 901–904. [Google Scholar]
  • 23.Bajaj P, Kale S, Ballary C, et-al Comparative efficacy and safety and tolerability ofparenteral parecoxib sodium and parenteral diclofenac sodium in relieving post operative pain following general and orthopedic surgery. Indian Medical Gazette. In press.
  • 24.Dukes M.N. Drugdex Evaluation on Diclofenac. vol 121. January–September 2004. Side effects of drugs. (Thomson Micromedex® Health Care Series 1974–2004). [CD-ROM] [Google Scholar]
  • 25.Michalevicz R., Seligsohn U. Clinical bleeding due to diclofenac (Voltaren) Arthritis Rheum. 1982;25:599. doi: 10.1002/art.1780250521. [DOI] [PubMed] [Google Scholar]
  • 26.Cheer S.M., Goa K.L. Parecoxib (parecoxib sodium) Drugs. 2001;61:1133–1141. doi: 10.2165/00003495-200161080-00010. [DOI] [PubMed] [Google Scholar]
  • 27.Barton S.F., Langeland F.F., Snabes M.C. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology. 2002;97:306–314. doi: 10.1097/00000542-200208000-00004. [DOI] [PubMed] [Google Scholar]
  • 28.Rasmussen G.L., Steckner K., Hogue C. Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. Am J Orthop. 2002;31:336–343. [PubMed] [Google Scholar]
  • 29.Desjardins P.J., Grossman E.H., Kuss M.E. The injectable cyclooxygenase2-specific inhibitor parecoxib sodium has analgesic efficacy when administered preoperatively. Anesth Analg. 2001;93:721–727. doi: 10.1097/00000539-200109000-00036. [DOI] [PubMed] [Google Scholar]
  • 30.Joshi G.P., Viscusi E.R., Gan T.J. Effective treatment of laparoscopic cholecystectomy pain with intravenous followed by oral COX-2 specific inhibitor. Anesth Analg. 2004;98:336–342. doi: 10.1213/01.ANE.0000093390.94921.4A. [DOI] [PubMed] [Google Scholar]
  • 31.Bajaj P., Ballary C., Dongre N. Role of parecoxib in pre-emptive analgesia: Comparison of the efficacy and safety of pre- and post-operative parecoxib in patients undergoing generalsurgery. J Ind Med Assoc. 2004;102:272. [PubMed] [Google Scholar]; Bajaj P., Ballary C., Dongre N. Role of parecoxib in pre-emptive analgesia: Comparison of the efficacy and safety of pre- and post-operative parecoxib in patients undergoing generalsurgery. J Ind Med Assoc. 2004;102:274. [PubMed] [Google Scholar]
  • 31.Bajaj P., Ballary C., Dongre N. Role of parecoxib in pre-emptive analgesia: Comparison of the efficacy and safety of pre- and post-operative parecoxib in patients undergoing generalsurgery. J Ind Med Assoc. 2004;102:276–278.. [PubMed] [Google Scholar]
  • 32.Born G.V. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nauhni Tr Vissh Med last Sofiia. 1962;194:927–929. doi: 10.1038/194927b0. [DOI] [PubMed] [Google Scholar]
  • 33.Frerichs J.A., Janis L.R. Preemptive analgesia in foot and ankle surgery. Clin Podiatr Med Surg. 2003;20:237–256. doi: 10.1016/S0891-8422(03)00005-3. [DOI] [PubMed] [Google Scholar]
  • 34.Gabriel S.E., Jaakimainen L., Bombardier C. Risk for serious gastrointestinal complications related to the use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991;115:787–796. doi: 10.7326/0003-4819-115-10-787. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES